ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

Patients with non–small cell lung carcinoma (NSCLC) with activating mutations in epidermal
growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and …

Patients with non–small cell lung cancer (NSCLC) harboring activating mutations in the
epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine …

The first generation EGFR TKIs gefitinib and erlotinib provide significant clinical benefit in
patients with advanced lung adenocarcinoma harbouring activating EGFR mutants …

Lung cancer is the leading cause of cancer-related death in the world. Prior to the era of
targeted therapy, platinum-based doublet chemotherapy was the first-line therapy of choice …

7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …

Introduction Osimertinib is a standard first-line treatment for non–small cell lung cancer
(NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR) …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2014; 3
(6): 360-362 www. tlcr. org abnormality is identified. While limitations exist with performing …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …

PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …